Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paulo Cesar Maciag

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Current Opinion in Molecular Therapeutics|October 27, 2005
Listeria-based vaccines for cancer treatmentYvonne Paterson, Paulo Cesar Maciag
Current Opinion in Molecular Therapeutics|June 28, 2005
Technology evaluation: HspE7 (Stressgen)Paulo Cesar Maciag, Yvonne Paterson
Vaccine|April 25, 2009
The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervixPaulo Cesar Maciag, Sinisa Radulovic, John Rothman
Future Oncology (London, England)|April 21, 2009
HPV variants and HLA polymorphisms: the role of variability on the risk of cervical cancerPatrícia Savio de Araujo Souza, Laura Sichero, Paulo Cesar Maciag
Clinical and Vaccine Immunology : CVI|November 21, 2008
Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapyAnu Wallecha, Paulo Cesar Maciag, Sandra Rivera, et al.
Cancer Research|October 3, 2008
Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculaturePaulo Cesar Maciag, Matthew M Seavey, Zhen-Kun Pan, et al.
Advances in Applied Microbiology|February 11, 2009
Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeuticsAnu Wallecha, Kyla Driscoll Carroll, Paulo Cesar Maciag, et al.
Journal of Medical Virology|July 24, 2008
Human papillomavirus type 16 variants in cervical cancer from an admixtured population in BrazilKatiana Junes-Gill, Laura Sichero, Paulo Cesar Maciag, et al.
Archives of Otolaryngology--Head & Neck Surgery|September 22, 2010
Effect of a novel DNA vaccine on angiogenesis and tumor growth in vivoKibwei A McKinney, Nada Al-Rawi, Paulo Cesar Maciag, et al.
Viral Immunology|May 14, 2009
Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunizationWaleed Mustafa, Paulo Cesar Maciag, Zhen-kun Pan, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Current Opinion in Molecular Therapeutics|October 27, 2005
Listeria-based vaccines for cancer treatmentYvonne Paterson, Paulo Cesar Maciag
Current Opinion in Molecular Therapeutics|June 28, 2005
Technology evaluation: HspE7 (Stressgen)Paulo Cesar Maciag, Yvonne Paterson
Vaccine|April 25, 2009
The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervixPaulo Cesar Maciag, Sinisa Radulovic, John Rothman
Future Oncology (London, England)|April 21, 2009
HPV variants and HLA polymorphisms: the role of variability on the risk of cervical cancerPatrícia Savio de Araujo Souza, Laura Sichero, Paulo Cesar Maciag
Clinical and Vaccine Immunology : CVI|November 21, 2008
Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapyAnu Wallecha, Paulo Cesar Maciag, Sandra Rivera, et al.
Cancer Research|October 3, 2008
Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculaturePaulo Cesar Maciag, Matthew M Seavey, Zhen-Kun Pan, et al.
Advances in Applied Microbiology|February 11, 2009
Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeuticsAnu Wallecha, Kyla Driscoll Carroll, Paulo Cesar Maciag, et al.
Journal of Medical Virology|July 24, 2008
Human papillomavirus type 16 variants in cervical cancer from an admixtured population in BrazilKatiana Junes-Gill, Laura Sichero, Paulo Cesar Maciag, et al.
Archives of Otolaryngology--Head & Neck Surgery|September 22, 2010
Effect of a novel DNA vaccine on angiogenesis and tumor growth in vivoKibwei A McKinney, Nada Al-Rawi, Paulo Cesar Maciag, et al.
Viral Immunology|May 14, 2009
Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunizationWaleed Mustafa, Paulo Cesar Maciag, Zhen-kun Pan, et al.
Pageof 2